Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study) Authors: Somnath Chakraborty, Jay U Sheth, Santanu Ganguly, Preesha Reddy Published: 2026 ABSTRACT AbstractPurposeTo evaluate the anatomical and functional efficacy of bevacizumab biosimilar (Bevatas®) in the treatment of diabetic macular edema (DME) in a real-world Indian clinical setting.Patients and MethodsThis retrospective observational study included 123 eyes of patients with center-involving DME (CI-DME) treated with intravitreal biosimilar of bevacizumab (IVBb) between January 2022 and December 2025. Eyes received three loading doses followed by pro-re-nata regimen with supplemental focal laser as needed. Best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure, (IOP), and optical coherence tomography (OCT) biomarkers were assessed at baseline and at months 1, 2, 3, 6, and 12. Treatment burden and safety outcomes were recorded.ResultsMean visual acuity improved from 0.591 ± 0.276 logMAR at baseline to 0.249 ± 0.079 logMAR at month 12, representing a gain of 0.342 logMAR (P<0.001). Central macular thickness decreased from 469.9 ± 132.4 µm to 196.9 ± 51.8 µm (P<0.001). Hyperreflective foci (HRF), present in 35.8% of eyes at baseline, resolved completely by month 1 and remained absent throughout follow-up. Eyes received a mean of 4.6 ± 1.3 injections over 12 months. Supplemental focal laser was administered in 55.3% of eyes. IOP remained stable Anatomical response showed fluctuation at month 6, with partial recurrence of edema, followed by recovery at month 12. No significant ocular or systemic adverse events were noted.ConclusionBevacizumab biosimilar produces meaningful visual and anatomical improvement in CI-DME in a real-world Indian setting. The modest injection frequency reflects practical treatment patterns in resource-limited environments. IVBb represents an accessible and affordable anti-vascular endothelial growth factor (anti-VEGF) option for DME management in India and similar healthcare contexts.Keywords: diabetic macular edema, bevacizumab, biosimilar, Bevatas Introduction Diabetic macular edema (DME) remains the leading cause of visual impairment among working-age adults with diabetes mellitus (DM).1,2 With an estimated 77 million people living with diabetes in India and projections suggesting this number will exceed 134 million by 2045, the burden of diabetic retinopathy and its complications presents a major public health challenge.1,3 Macular edema develops in approximately 10% of diabetic patients and accounts for most cases of vision loss attributable to diabetes.3,4 The pathophysiology centers on breakdown of the blood-retinal barrier driven by vascular endothelial growth factor and inflammatory mediators, leading to fluid accumulation in the macula and photoreceptor dysfunction.5,6 Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed DME management over the past 18 years.1–7 The DRCR Protocol T trial established that aflibercept, ranibizumab, and bevacizumab all improve visual outcomes compared with laser photocoagulation alone, with differences in efficacy relating primarily to baseline visual acuity.8,9 While aflibercept and ranibizumab carry formal regulatory approval for DME in most jurisdictions, bevacizumab has been widely adopted as an off-label alternative based on comparable efficacy and substantially lower cost.10–12 The economic dimension of anti-VEGF therapy assumes particular importance in India and other low- and middle-income countries (LMICs). Aflibercept and ranibizumab carry prohibitive costs for most patients, with single injections priced at levels that exceed monthly household income for large segments of the population.12–14 Even originator bevacizumab, while less expensive than purpose-developed agents, remains financially challenging when patients require multiple injections over months to years. These economic barriers create substantial treatment gaps, with many patients unable to access or sustain anti-VEGF therapy despite clear clinical need.15–17 Biosimilar bevacizumab formulations have emerged as potential solutions to the access problem. Bevatas®, manufactured by Intas Pharmaceuticals in India, represents one such biosimilar. The molecule has demonstrated physicochemical similarity to reference bevacizumab and has undergone clinical evaluation in retinal vein occlusion (RVO) and retinopathy of prematurity (ROP) by our group.18,19 However, real-world evidence for its use in DME remains limited, particularly regarding treatment patterns, injection burden, and outcomes in typical Indian clinical practice. This study aimed to evaluate the anatomical and functional outcomes of intravitreal biosimilar of bevacizumab (Bevatas; IVBb) in DME over 12 months of real-world follow-up. We sought to characterize both efficacy and treatment burden in a setting where cost constraints, variable follow-up compliance, and practical barriers to sustained therapy influence clinical outcomes. Understanding how the IVBb performs in this context provides evidence to guide treatment decisions for the millions of LMIC patients with DME who require accessible and sustainable anti-VEGF options. Materials and Methods Study Design and Patient Selection This retrospective observational study included 123 eyes of 123 patients with center-involving DME (CI-DME) treated with IVBb at the Retina Institute of Bengal in Siliguri, India between between January 2022-December 2025. Patients were identified from electronic medical records. Inclusion criteria required documented CI-DME with central macular thickness (CMT) exceeding 300 µm on spectral-domain optical coherence tomography (SD-OCT; Heidelberg Spectralis), minimum 12-month follow-up, and treatment-naive status for anti-VEGF therapy. Only one eye per patient was included in the analysis; when both eyes met eligibility criteria, the eye with worse baseline visual acuity was selected to avoid inter-eye correlation. Eyes with concurrent retinal pathology, prior intravitreal therapy, active proliferative diabetic retinopathy requiring panretinal photocoagulation, or media opacity precluding adequate imaging were excluded. Institutional Review Board approval was obtained (Retina Institute Of Bengal Ethics Committee, Siliguri, India; RIB/IRB/0005/2025), and all procedures conformed to the tenets of the Declaration of Helsinki. Written informed consent for treatment anonymised data use was obtained from all patients. Treatment Protocol All eyes received 1.25 mg IVBb (0.05 mL; Bevatas®, Intas Pharmaceuticals, India) administered via pars plana injection under sterile conditions. Treatment followed a pro-re-nata (PRN) protocol with monthly monitoring. Retreatment decisions were based on persistent or recurrent DME evidenced by clinical examination and OCT imaging. Supplemental focal laser photocoagulation targeting microaneurysms and areas of focal leakage was performed at treating physician discretion. Follow-up examinations were scheduled at months 1, 2, 3, 6, and 12 after initial injection. Outcome Measures Primary outcomes included best-corrected visual acuity (BCVA) measured using Snellen charts and converted to logarithm of minimum angle of resolution (LogMAR), and CMT measured on spectral-domain OCT. Secondary outcomes comprised presence of hyperreflective foci (HRF) on OCT and intraocular pressure (IOP). HRF were assessed on SD-OCT scans by a single masked grader who was a fellowship-trained retina specialist (S.C.) with over 15 years of experience in retinal imaging interpretation. Treatment burden was assessed by total number of injections received and proportion of eyes requiring supplemental focal laser. Safety outcomes included IOP elevation, endophthalmitis, and other injection-related complications. Statistical Analysis Continuous variables were expressed as mean ± standard deviation. Snellen visual acuity measurements were converted to logarithm of minimum angle of resolution (logMAR) values for statistical analysis. Longitudinal changes at each prespecified follow-up visit were assessed by comparing values with baseline using paired t-tests. Changes in categorical variables, including the presence of hyperreflective foci, were analyzed using McNemar’s test. Because the analyses were intended to describe within-eye changes over time in this retrospective cohort, no formal repeated-measures model or multiplicity adjustment was applied; therefore, these comparisons should be interpreted as exploratory. Statistical significance was defined as P<0.05. All analyses were performed using SPSS 23.0 software (SPSS Inc., Chicago, IL, USA). Results Baseline Characteristics One hundred twenty-three eyes of patients with DME met inclusion criteria. Mean age was 56.4 ± 8.1 years and mean diabetes duration was 10.0 ± 5.6 years (Table 1). The cohort included 70 males (56.9%) and 53 females (43.1%). Systemic hypertension was present in 52.8% of patients. Baseline visual acuity was 0.591 ± 0.276 logMAR and baseline central macular thickness was 469.9 ± 132.4 µm. HRF were identified in 44 eyes (35.8%) at baseline. Table 1Baseline Demographic and Clinical Characteristics of the Study PopulationVariableValueNumber of eyes123Age, mean ± SD (years)56.4 ± 8.1DM duration, mean ± SD (years)10.0 ± 5.6Female, n (%)53 (43.1%)Male, n (%)70 (56.9%)Systemic hypertension, n (%)65 (52.8%)Right eyes, n (%)62 (50.4%)Left eyes, n (%)61 (49.6%)Abbreviations: SD, Standard deviation; DM, Diabetes Mellitus. Baseline Demographic and Clinical Characteristics of the Study Population Abbreviations: SD, Standard deviation; DM, Diabetes Mellitus. Best-Corrected Visual Acuity Outcomes Mean visual acuity improved progressively from baseline through month 3, with gains of 0.231 logMAR at month 1, 0.307 logMAR at month 2, and 0.348 logMAR at month 3 (all P<0.001). Visual acuity at month 6 showed some regression to 0.398 ± 0.237 logMAR, representing a gain of 0.193 logMAR from baseline, though this remained statistically significant (P<0.001). By month 12, vision recovered to 0.249 ± 0.079 logMAR, representing a final gain of 0.342 logMAR from baseline (P<0.001) (Table 2). Table 2Visual, Anatomical, Intraocular Pressure, and Hyperreflective Foci Outcomes Over 12 Months After Bevacizumab Biosimilar (Bevatas) TreatmentVisitBCVA, logMAR Mean ± SDP-value versus BaselineCMT, µm Mean ± SDP-value versus BaselineIOP, mmHg Mean ± SDP-value versus BaselineNumber of Eyes with HRFP-value versus BaselineBaseline0.591 ± 0.276NA469.854 ± 132.431NA17.358 ± 2.869NA44NAMonth 10.362 ± 0.151<0.001*245.333 ± 54.444<0.001*16.732 ± 2.627<0.001*0<0.001*Month 20.284 ± 0.098<0.001*204.829 ± 33.991<0.001*16.585 ± 2.469<0.001*0<0.001*Month 30.243 ± 0.087<0.001*186.740 ± 25.138<0.001*16.650 ± 2.315<0.001*0<0.001*Month 60.398 ± 0.237<0.001*334.667 ± 145.247<0.001*16.626 ± 2.338<0.001*0<0.001*Month 120.249 ± 0.079<0.001*196.878 ± 51.770<0.001*16.911 ± 2.7610.020*0<0.001*Note: *Statistically significant.Abbreviations: BCVA, Best-corrected visual acuity; SD, Standard deviation; CMT, Central macular thickness; IOP, Intraocular pressure; HRF, Hyperreflective foci; NA, Not applicable. Visual, Anatomical, Intraocular Pressure, and Hyperreflective Foci Outcomes Over 12 Months After Bevacizumab Biosimilar (Bevatas) Treatment Note: *Statistically significant. Abbreviations: BCVA, Best-corrected visual acuity; SD, Standard deviation; CMT, Central macular thickness; IOP, Intraocular pressure; HRF, Hyperreflective foci; NA, Not applicable. Anatomical Outcomes CMT decreased significantly following initial treatment. Mean CMT fell from 469.9 ± 132.4 µm at baseline to 245.3 ± 54.4 µm at month 1, representing a reduction of 224.5 µm (P<0.001). Further improvement occurred through month 3, with CMT reaching 186.7 ± 25.1 µm, a reduction of 283.1 µm from baseline (P<0.001). Month 6 showed significant anatomical deterioration, with mean CMT rising to 334.7 ± 145.2 µm, though this remained 135.2 µm below baseline (P<0.001). By month 12, CMT recovered to 196.9 ± 51.8 µm, representing a final reduction of 273.0 µm from baseline (P<0.001). HRF resolved completely by month 1 in all 44 eyes that demonstrated this biomarker at baseline, and remained absent at all subsequent visits through month 12 (P<0.001) (Table 2). Treatment Burden and Safety Eyes received a mean of 4.6 ± 1.3 intravitreal injections over the 12-month follow-up period. Supplemental focal laser photocoagulation was performed in 68 eyes (55.3%), with treated eyes receiving a mean of 1.3 ± 0.5 laser sessions. IOP remained stable throughout the study, with small decreases from baseline observed at all time points (all P<0.05). Mean IOP decreased from 17.4 ± 2.9 mmHg at baseline to 16.9 ± 2.8 mmHg at month 12 (P=0.020) (Table 2). No ocular or systemic adverse events were observed throughout the study period. Figures 1 and 2 are representative cases from the study population. A 52-year-old male with center-involving diabetic macular edema (DME) in the right eye. Baseline spectral-domain optical coherence tomography (SD-OCT) demonstrated significant macular edema with BCVA of 20/80 (A). Following three loading doses of intravitreal bevacizumab biosimilar, BCVA improved to 20/40 at 1 month with reduction in edema (B), and to 20/32 at 3 months with near-complete anatomical resolution (C). At 6 months, recurrent DME with decline in BCVA to 20/63 was observed (D), prompting additional intravitreal injections and focal laser photocoagulation. At 12 months, BCVA improved to 20/32 with complete resolution of DME on SD-OCT (E). A 61-year-old female with center-involving diabetic macular edema (DME) in the right eye. Baseline spectral-domain optical coherence tomography (SD-OCT) showed DME with BCVA of 20/63 (A). After three loading doses of intravitreal bevacizumab biosimilar, BCVA improved to 20/40 at 1 month despite mild persistent edema on SD-OCT (B). By 3 months, anatomical resolution of DME was achieved with stable visual acuity (C). At 6 months, recurrent DME with reduction in BCVA to 20/80 was noted (D), and additional intravitreal injections with focal laser photocoagulation were administered. At 12 months, BCVA improved to 20/40 with mild residual edema persisting on SD-OCT (E). Discussion The present study shows that intravitreal Bevatas, an Indian bevacizumab biosimilar, achieved substantial and sustained improvements in both BCVA and CMT over 12 months in eyes with DME, with a mean of 4.6 injections and frequent use of adjunct focal laser in an Indian clinical setting. Mean BCVA improved by approximately one-third of a logMAR line from baseline and remained better than baseline at all visits, while mean CMT almost halved by month 3 and remained significantly reduced at one year despite some midcourse fluctuation. These outcomes, achieved with a relatively modest injection burden, are clinically meaningful for LMIC retina practice, where the key challenge is not the biological efficacy of anti-VEGF agents but the feasibility of delivering and sustaining intensive treatment over years of chronic disease. The most relevant benchmark for these results is DRCR.net Protocol T, which compared aflibercept, ranibizumab, and bevacizumab in CI-DME.8,9 In that trial, all three agents produced substantial visual gains, with aflibercept showing an early advantage in eyes with poorer baseline vision, but differences between agents narrowed over time and were relatively modest at two years.8 Importantly, Protocol T achieved its outcomes with structured monthly monitoring and a median first-year injection count that was roughly double the 4.6 injections delivered in the present cohort.8 Despite this much lower treatment intensity, the magnitude and durability of BCVA improvement in the IVBb-treated eyes were broadly consistent with the range reported for bevacizumab in Protocol T, especially for eyes starting with worse than 20/50 vision.8,9 Cochrane reviews of anti-VEGF therapy in DME have emphasized that all three major agents, aflibercept, ranibizumab, and bevacizumab, offer clear advantages over laser alone, and that average visual outcomes are often similar when dosing regimens are sufficiently intensive.20 Seen against this backdrop, the present data suggest that IVBb can approximate trial-grade bevacizumab performance in routine practice, provided enough injections are delivered during the early treatment phase, even if overall intensity remains below ideal. The pattern of CMT response offers further insight. A marked reduction occurred by month 3, followed by partial anatomical worsening at month 6 and renewed improvement by month 12. This mid-year “dip” may reflect a common real-world pattern seen with PRN regimens, in which retreatment intervals often lengthen after initial gains and edema can recur before the next injection.21,22 The subsequent recovery of CMT, together with stable visual acuity at one year, is compatible with delayed retreatment or fluctuating disease control during the middle of follow-up, although the present data do not allow this to be proven. Rather, these findings highlight a recognized challenge when translating Protocol T-like treatment strategies into day-to-day LMIC practice.21,22 The management of DME in India must be understood within a broader context of out-of-pocket health expenditure, variable insurance coverage, and competing priorities in diabetic care. Indian guidelines endorse anti-VEGF therapy as first-line treatment for center-involving DME, but they also explicitly recognize that sustained monthly or treat-and-extend regimens are difficult to maintain for many patients, particularly in the public sector and in lower-income groups.1,10 Real-world series from India and other LMICs consistently show fewer injections than in pivotal trials and smaller average visual gains, reflecting a mixture of cost pressures, travel distance, loss of wages, and clinic capacity limitations.11,18,19,21,22 Within this environment, bevacizumab has become the workhorse anti-VEGF agent because it is far less expensive than ranibizumab or aflibercept while offering comparable average benefit when used adequately. Indian cost-effectiveness analyses demonstrate that lower-cost agents provide better value by enabling treatment for more patients within fixed budgets, and biosimilars such as Bevatas extend this advantage by improving affordability and access for sustained therapy.13,23 The treatment pattern in this cohort, with a mean of 4.6 injections over 12 months, PRN dosing, and frequent adjunctive focal laser, reflects the cost-sensitive reality of LMIC practice. For many patients, particularly those from rural areas or with competing medical expenses, a front-loaded approach followed by less frequent visits is often more feasible than fixed monthly regimens. The observed visual and anatomical improvements suggest that an affordable biosimilar can provide clinically meaningful benefit in routine Indian DME care, where sustained high-intensity treatment is often difficult to maintain. In this setting, the PRN regimen appears to offer a pragmatic balance between efficacy, cost, and treatment burden: early intensive therapy likely contributed to the gains seen by months 2–3, while deferred retreatment in stable eyes may have contributed to the transient rise in CMT at month 6, consistent with patterns reported in real-world anti-VEGF series.11,18,19,21,22 The high rate of supplemental focal laser in our cohort (55.3%) also aligns with the broader Protocol T experience,8 in which focal/grid laser was ultimately required in approximately 64% of bevacizumab-treated eyes, 52% of ranibizumab-treated eyes, and 41% of aflibercept-treated eyes over 2 years. In contrast to Protocol T,8 where laser was incorporated within a structured retreatment algorithm and largely as adjunctive/rescue therapy, its earlier use here likely reflects real-world LMIC practice, where clinicians often aim to consolidate anatomical gains while limiting long-term injection burden and cost. This combination strategy may have contributed to the recovery of CMT by month 12 despite relatively few injections, although the retrospective design and lack of a non-laser comparison group prevent definitive conclusions. More broadly, these findings underscore that in LMIC retina care, treatment decisions are often shaped as much by economics and access as by disease biology, with affordability and visit feasibility determining whether sustained anti-VEGF therapy is realistically achievable. The changes in HRF in this cohort are noteworthy. HRF are increasingly regarded as a structural OCT biomarker of inflammatory and exudative activity in diabetic retinal disease and have been linked to disruption of the blood-retinal barrier, activated microglial cells, lipid extravasation, and early hard exudate formation. Prior studies have associated HRF with greater disease severity, chronic edema, and poorer visual outcomes in DME, while reduction in HRF following anti-VEGF therapy has been proposed as a marker of favorable treatment response and reduced inflammatory activity.24–26 In the present study, HRF were identified in 35.8% of eyes at baseline and were not observed on subsequent follow-up visits after treatment initiation. This finding may suggest improvement in inflammatory or exudative retinal changes following IVBb-based therapy, with adjunctive focal laser where used, although it should be interpreted cautiously given the retrospective design and qualitative nature of HRF assessment. In addition, HRF grading was performed by a single masked retina specialist, and interobserver reproducibility was therefore not assessed. The early CMT response, followed by mid-course worsening and later recovery, is consistent with chronic disease in which vascular permeability and low-grade inflammation persist. With a mean diabetes duration of 10 years, these eyes likely had established microvascular damage and may have required more sustained anti-VEGF exposure. The improvement in both CMT and HRF by month 12 suggests continued responsiveness to retreatment and reinforces the importance of follow-up and timely reinjection. For clinicians, this indicates that IVBb can remain effective over repeated cycles, and anatomical fluctuation does not necessarily imply loss of drug effect, but rather reflect modifiable treatment intensity. Within the limits of the available data, the safety profile of IVBb in DME appears consistent with that reported for reference bevacizumab and other anti-VEGF agents.2,12,27–29 Mean IOP remained slightly lower than baseline at all follow-up visits, with small but statistically significant reductions and no signal of sustained IOP elevation at the cohort level. However, the magnitude of reduction was modest and not clinically meaningful, as no eye developed ocular hypotony or pressure-related adverse events. There is no clear biological explanation for this finding, and the small reduction observed may simply reflect physiological variation in serial IOP measurements over time rather than a treatment-related effect. The complete resolution of HRF further supports a favorable structural response without OCT evidence of deleterious effects. No significant ocular or systemic adverse events were observed. Consistent with this, our prior work in RVO and ROP did not identify any safety concerns with this biosimilar.18,19 While these findings are reassuring, continued pharmacovigilance and larger real-world datasets remain important as use expands in LMIC settings. Biosimilar introduction in ophthalmology raises specific questions, including the degree of clinical evidence needed for each indication and how to manage switching between originator and biosimilar products.30–34 Indian regulatory pathways require demonstration of structural and functional similarity to the reference molecule and at least one supportive clinical indication, but do not mandate large head-to-head trials in every ophthalmic disease where bevacizumab is commonly used off-label.34 The current biosimilar has undergone physicochemical characterization and clinical evaluation in RVO and ROP,18,19 and the present data extend its evidence base into DME, the most common indication for intravitreal bevacizumab in India. From the perspective of Indian and LMIC retina practice, the central question is less whether biosimilars are perfectly interchangeable with originator products and more whether they can safely expand access to anti-VEGF therapy for patients who would otherwise receive no treatment or purely laser-based care. When budgets are constrained at both patient and system levels, the choice is often between a biosimilar and no anti-VEGF at all, rather than between a biosimilar and a branded agent. In that setting, the demonstration that IVBb can deliver trial-consistent improvements in vision and OCT parameters over 12 months, using a pragmatic injection schedule, provides reassuring evidence that cost savings do not necessarily come at the expense of clinical effectiveness. This study has several important limitations. The analysis is based on aggregate data from a single center, and the underlying retrospective design limits the ability to adjust for confounders. The absence of a concurrent control group precludes direct comparison with reference bevacizumab, other anti-VEGF agents, or different dosing protocols; inferences about relative performance rely on indirect comparison with published trials and real-world series. In particular, comparisons with Protocol T should be interpreted cautiously, as differences in retreatment algorithms, follow up intensity, and patient selection limit direct comparability between structured clinical trial data and routine practice outcomes. This was also not a comparative study against conventional bevacizumab, and prospective comparative studies will be needed to assess the relative performance of the biosimilar more definitively. Treatment intensity and the use of focal laser were determined by physician judgment rather than a rigid protocol, introducing heterogeneity that may influence outcomes but also reflecting real-world practice patterns in LMICs. The 12-month follow-up, while clinically meaningful, does not address longer-term durability in a disease that often requires multi-year management. Finally, no direct cost or quality-of-life metrics were collected, so health-economic interpretations rely on external Indian cost-effectiveness literature and known price differentials rather than patient-level expenditure data. Despite these limitations, the present study offers several practical messages for retina specialists working in India and similar LMIC settings. First, IVBb-based regimens can achieve substantial and durable improvements in BCVA and CMT over 12 months in DME, even when the average number of injections is lower than in clinical trials and focal laser is used judiciously as an adjunct. Second, the complete resolution of HRF and sustained CMT reduction indicate that IVBb is capable of modifying both fluid and structural biomarkers associated with more severe disease, supporting its use in treatment-naïve eyes with significant edema. Third, the favorable balance between outcomes and injection burden suggests that, in cost-constrained environments, a strategy of early intensive IVBb therapy followed by individualized PRN retreatment and selective laser is a realistic and clinically credible approach. For many patients in LMICs, an affordable biosimilar is the only route to sustained anti-VEGF therapy, and the alternative is often undertreatment or reliance on laser alone. In that context, the ability of IVBb to deliver meaningful visual and anatomical gains with a modest number of injections supports its role as a first-line option for CI-DME, reserving more expensive branded agents or steroid implants for non-responders or specific clinical scenarios. For LMIC retina practice more broadly, these findings reinforce the principle that expanding access to any effective anti-VEGF therapy, through biosimilars, pooled compounding, or public procurement, may yield greater population-level benefit than concentrating limited funds on a smaller number of patients treated with premium agents. Conclusion The bevacizumab biosimilar (Bevatas) was associated with clinically meaningful visual and anatomical improvement in DME within a real-world Indian practice setting. Notably, these outcomes were achieved despite a relatively low injection burden, reflecting the practical constraints of routine care, including treatment cost, follow-up variability, and patient adherence. Although formal cost-effectiveness analyses were not performed, the present findings suggest that biosimilar anti-VEGF therapy may offer a feasible approach to expanding access to DME treatment in resource-constrained healthcare environments. Taken together, these data support the consideration of IVBb as a practical therapeutic option for DME management in India and other LMIC settings. Disclosure J.U.S.: Shantilal Shanghvi Foundation (SSF) (not relevant to the work under consideration). SC, SG, PR report no conflicts of interest in this work. References